BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE) vs. 12% for glimepiride, a sulfonylurea ATP-dependent KATP...
...Targets: DPP-4 (CD26) - Dipeptidyl peptidase-4; GM-CSF (CSF2) - Granulocyte macrophage colony-stimulating factor; KATP - ATP-dependent potassium channel BioCentury...
BioCentury | Aug 3, 2018
Clinical News

Boehringer, Lilly's Tradjenta meets in first CV outcomes trial

...Tradjenta and other diabetes candidates under a 2011 deal. Tradjenta and Amaryl, a sulfonylurea ATP-dependent potassium channel (KATP...
BioCentury | Feb 11, 2016
Distillery Therapeutics

Therapeutics: Downstream regulatory element antagonistic modulator (DREAM); ATP-dependent potassium channel (KATP)

...of DREAM increased survival compared with unmodified DREAM expression. In cell-based DREAM activity assays, the KATP...
...NovoNorm delayed symptom onset, decreased striatal atrophy and increased motor coordination compared with a non-DREAM-binding KATP...
...that inhibits KATP, to treat diabetes. TARGET/MARKER/PATHWAY: Downstream regulatory element antagonistic modulator (DREAM) ; ATP-dependent potassium channel (KATP...
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: ATP-dependent potassium channel (KATP)

...Neurology INDICATION: Alzheimer's disease (AD) Mouse studies suggest KATP agonists could help prevent AD in patients...
...compared with vehicle. In mouse models of AD including glucose challenge, intrahippocampal infusion of a KATP...
...Kir6.2 ( KCNJ11 ) in mediating the effects of hyperglycemia on Aβ production. TARGET/MARKER/PATHWAY: ATP-dependent potassium channel (KATP...
BioCentury | Apr 6, 2015
Clinical News

Diazoxide choline controlled release: Phase I data

...Calif. Product: Diazoxide choline controlled release (DCCR) Business: Endocrine/Metabolic Molecular target: ATP-dependent potassium channel (KATP) Description: ATP-dependent potassium channel (KATP...
BioCentury | Jul 14, 2014
Clinical News

Diazoxide choline controlled release: Phase I started

...Calif. Product: Diazoxide choline controlled release (DCCR) Business: Endocrine/Metabolic Molecular target: ATP-dependent potassium channel (KATP) Description: ATP-dependent potassium channel (KATP...
BioCentury | Jun 23, 2014
Clinical News

Diazoxide choline controlled release regulatory update

...Drug designation to Essentialis’ diazoxide choline controlled release (DCCR) to treat Prader-Willi syndrome. The ATP-dependent potassium channel (KATP...
BioCentury | Jun 5, 2014
Strategy

Sanford-Burnham goes fourth

...Tanabe Pharma; Johnson & Johnson (NYSE:JNJ) Fastic/Starlix nateglinide d-Phenylalanine amino acid derivative that blocks ATP-dependent potassium channel (KATP...
BioCentury | Jul 1, 2013
Product Development

POC for APOCIIIRx

...to treat hypertriglyceridemia. In a Phase II trial, Essentialis Inc. 's diazoxide choline, an ATP-dependent potassium channel (KATP...
BioCentury | Mar 18, 2013
Emerging Company Profile

gIcare: Colonoscopy comfort

...parent product in the U.S. Hydrogen sulfide regulates neuronal function by multiple mechanisms including ATP-dependent potassium channel (KATP...
Items per page:
1 - 10 of 20